Objective: This study aims to determine whether menopausal symptoms differed between women with chronic kidney disease (CKD) and women without CKD, and whether CKD modified associations of late vasomotor symptoms (VMS) with mortality and/or cardiovascular events.
V asomotor symptoms (VMS) are common menopausal symptoms, occurring in 30% to 50% of perimenopausal and in 30% to 80% of postmenopausal women. 1 Although the pathogenesis of VMS remains incompletely understood, VMS are thought to be caused by thermoregulatory dysfunction leading to exaggerated activation of heat dissipation, including peripheral vasodilation and sweating. 2 VMS have been associated with a higher prevalence of cardiovascular risk factors and subclinical markers of cardiovascular disease (CVD). [3] [4] [5] [6] [7] Consequently, VMS may help to identify women at heightened cardiovascular risk. Indeed, Women's Health Initiative (WHI) participants who developed VMS after menopause (late VMS) were at increased risk for cardiovascular events and mortality, whereas women with early VMS were at lower risk for cardiovascular events and mortality than women who never experienced VMS. 8 Chronic kidney disease (CKD) has been reported to affect 15% of all women in the United States, 9 but relatively little is known about the relationship between CKD and menopause. Women with end-stage renal disease demonstrate accelerated aging, with premature menopause, bone fractures, and cardiovascular events. [10] [11] [12] [13] [14] Women with earlier stages of CKD experience premature cardiovascular morbidity and may also experience an excess burden of fractures, 15, 16 yet studies of menopausal characteristics across the spectrum of kidney function are lacking.
In this study, we sought to explore the associations among CKD, menopausal symptoms (specifically VMS), mortality, and cardiovascular events. We hypothesized that women with CKD would have earlier onset of and more severe menopausal symptoms. Given that late VMS (ie, not present at menopause but appearing later) are associated with increased cardiovascular risk, we hypothesized that the association of late VMS with mortality and cardiovascular events would be magnified in women with CKD.
METHODS

Study population and data source
The WHI is an ongoing longitudinal study funded by the National Heart, Lung, and Blood Institute that was designed to identify risk factors for CVD, cancer, and osteoporosis in older women. The WHI consists of two major parts-a set of clinical trials and an observational study, both of which have been previously described. 17, 18 In brief, the WHI recruited a predominantly healthy, ethnically and socioeconomically diverse cohort of postmenopausal women (aged between 50 and 79 y) between 1993 and 1998, with follow-up planned initially through 2005 but extended first through 2010 then through 2015. Postmenopause was defined as no menses for at least 6 months among women aged 55 years or older, or no menses for at least 12 months among women aged 50 to 54 years. Women were excluded if they had any medical condition predicted to have less than a 3-year survival, had a condition that might impair adherence to the study protocol or retention, or were participating in a randomized intervention trial. Study protocols and written informed consent forms were approved by the institutional review boards at all participating institutions.
We used data from the WHI biomarker cohort (N ¼ 22,313), which is composed of 8,505 self-identified black participants and 3,502 self-identified Hispanic participants in the WHI observational study and clinical trials plus 10,306 white participants from the hormone trial, such that the biomarker cohort reflects the age distribution of the hormone trial population. Characteristics of women in the general WHI cohort and in the WHI biomarker cohort are presented in Table 1 , Supplemental Digital Content 1 (http://links. lww.com/MENO/A125).
Main predictor variable
Participants in the biomarker cohort had baseline blood samples collected, including serum creatinine, lipids, and glucose. Serum creatinine was measured at baseline at the University of Minnesota at Fairview, using the Roche enzymatic method on the Roche Modular P Analyzer (Roche Diagnostics Corp), and was calibrated to isotope dilution mass spectroscopy standard. The laboratory coefficient of variation was 2.3%. We computed estimated glomerular filtration rate (eGFR) using the Chronic Kidney Disease Epidemiology Collaboration equation. 19 CKD was defined as eGFR below 60 mL/minute/1.73 m 2 at study baseline.
Main outcomes
The main outcomes of this study were as follows: age at menopause and presence, severity, and timing/duration of VMS, defined as the presence of hot flashes or night sweats based on participant self-report at study baseline. Age at menopause was defined (according to a WHI algorithm) as the age at which a woman first experienced last menstrual bleeding, underwent bilateral oophorectomy, or began using hormone therapy (HT). If a woman had a hysterectomy but not a bilateral oophorectomy, her age at menopause was defined as the age at which she either began using HT or first had symptoms of menopause (eg, VMS). If a woman had a hysterectomy without a bilateral oophorectomy at age 50 years or older and she did not experience VMS and did not take HT, her age at menopause was defined as age at hysterectomy. If VMS were present, participants were asked to rate the symptoms as mild (symptoms did not interfere with usual activities), moderate (symptoms interfered somewhat with usual activities), or severe (symptoms were so bothersome that usual activities could not be performed). Severity of VMS was determined only among women who reported VMS at study entry.
Timing/duration of VMS was analyzed using categories previously defined by the WHI: (1) no VMS-women reported never experiencing VMS; (2) early VMS-women reported VMS that began before menopause but were not present at study baseline; (3) persistent VMS-women reported VMS that began before menopause and were present at study baseline; and (4) late VMS-women reported not having VMS before menopause but reported VMS at study baseline. 8 We also assessed whether CKD modified the associations of late VMS with all-cause mortality, coronary heart disease (CHD), and cerebrovascular accident (CVA). 20 Mortality was ascertained by hospitalization records from time of death and from the most recent relevant hospitalization before death (inhospital death), as well as autopsy records and death certificate diagnoses. Data were linked to the National Death Index of the National Center for Health Statistics throughout the study to ascertain cause of death in all participants. CHD was defined as hospitalized myocardial infarction (MI), definite silent MI, and coronary death. MI was defined by medical history, electrocardiograms, and results of cardiac enzymes/ troponins. CVA was defined as rapid onset of persistent (lasting >24 h) neurologic deficit attributed to obstruction or rupture of the brain arterial system and without evidence of other causes. Events were adjudicated by formally trained adjudicators after self-report through annual (observational study) or semiannual (clinical trial) questionnaires.
Covariates
We considered several baseline factors as covariates that might confound the association between CKD and VMS, including age, race/ethnicity (self-reported non-Hispanic white, Hispanic/Latino, black or African American), diabetes, hypertension, hyperlipidemia, CVD, body mass index, smoking history, alcohol intake, physical activity, past use of HT, and-in longitudinal analyses-active HT arm for HT clinical trial participants. Diabetes mellitus was defined as self-reported use of pills/insulin and/or serum fasting blood glucose level higher than 126 mg/dL. Hypertension was defined as systolic blood pressure higher than 140 mm Hg, diastolic blood pressure higher than 90 mm Hg, or use of pills for hypertension. Hyperlipidemia was defined as total cholesterol level higher than 240 mg/dL, low-density lipoprotein level higher than 160 mg/dL, or use of cholesterol-lowering medication. Smoking history, alcohol intake, prior CVD, past use of HT, and duration of HT use were ascertained by questionnaire. Physical activity was ascertained with a personal habits questionnaire and expressed as total metabolic equivalent of task per week.
Statistical analysis
We used descriptive statistics to characterize differences between women with CKD and women without CKD, including x 2 tests for categorical variables and independent t tests for continuous variables. We used polytomous logistic regression to determine unadjusted, demographics-adjusted, and multivariable-adjusted associations among CKD and VMS categories. We determined crude event rates for women with late VMS versus women without late VMS and for women with CKD versus women without CKD, using Kaplan-Meier plots. Unadjusted, demographics-adjusted, and multivariableadjusted proportional hazards regression (Cox) models were fit for each event. We confirmed the validity of proportionality assumption with graphical methods. The multivariableadjusted model included all aforementioned covariates. To test for differential associations among VMS status, mortality, and CVD events between participants with CKD at baseline and participants without CKD at baseline, we included a CKD Â VMS status interaction term in the multivariable model. We stratified analyses by baseline HT use and HT randomization arm. We conducted all analyses using SAS version 9.3 (SAS Institute, Cary, NC) and R version 3.0.1. 21 
RESULTS
Of the 22,313 participants in the biomarker cohort, 189 were missing serum creatinine information, 2,251 were missing baseline information on VMS, and 1,982 were missing other key covariates. Women missing any of these variables were excluded, resulting in a final cohort of 17,891 participants ( Fig. 1 , Supplemental Digital Content 1, http://links. lww.com/MENO/A125). By design, the cohort was ethnically diverse: 38% black, 16% Hispanic/Latina, and 46% white. Women who were excluded from this analysis were more likely to have CKD (6.7% vs 5.6%), more likely to have experienced menopause before age 45 years (35% vs 25%), and more likely to have used HT at baseline (44% vs 38%). They were also more likely to have experienced late VMS (43% vs 15%), less likely to have had early VMS (13% vs 25%), or less likely to have had no VMS (16% vs 29%). Other characteristics were not meaningfully different.
The analytic cohort included 1,007 women (5.6%) with CKD. The mean (SD) eGFR was 50.7 (9.1) and 89.9 (14.1) mL/minute/1.73 m 2 , respectively, in women with CKD and women without CKD. Compared with women without CKD, women with CKD were older; more likely to be black; more likely to have hypertension, diabetes, hyperlipidemia, CVD, or obesity; less physically active; less likely to be current smokers or alcohol drinkers; and less likely to have used HT before enrollment (Table 1) .
Menopause was more likely to occur before age 45 years in women with CKD than in women without CKD (26% vs 23%), but there was no difference in the prevalence of hysterectomy (1.2% vs 2.0%, P ¼ 0.16) or bilateral oophorectomy (18.8% vs 18.4%, P ¼ 0.44) in women with CKD versus women without CKD. Women with CKD were less likely to have VMS at baseline (38% vs 46%) than women without CKD. The frequency of severe VMS was not significantly different between women with CKD and women without CKD (Table 2) . Persistent VMS were more common in women without CKD than in women with CKD ( Fig. 1) .
In unadjusted analyses, CKD was associated with lower odds of persistent VMS (odds ratio, 0.60; 95% CI, 0.51-0.71) or late VMS (odds ratio, 0.80; 95% CI, 0.67-0.96) compared with women without CKD and with no VMS. After adjustment for demographics and other covariates, only the association between CKD and persistent VMS remained statistically significant ( Table 3) .
Across a median of 10.6 years, we recorded 2,366 deaths, 1,091 CHD events, and 775 CVA events. Women with late VMS had a higher risk of all-cause mortality (multivariableadjusted hazard ratio [HR], 1.16; 95% CI, 1.04-1.29). In this cohort, there was no significant association between late VMS and CHD or CVA before or after adjustment for CKD. As expected, baseline CKD was independently associated with all-cause mortality (multivariable-adjusted HR, 1.74; 95% CI, 1.54-1.97), CHD (HR, 1.60; 95% CI, 1.33-1.93), and CVA (HR, 1.52; 95% CI, 1.21-1.91). CKD did not modify the association of late VMS with any events (Table 4 ).
DISCUSSION
In this analysis, we characterized the menopausal transition in a diverse cohort of older women, with particular focus on CKD. We found that, relative to women with normal or nearnormal kidney function, women with CKD experienced earlier menopause, fewer VMS, and less persistent VMS. CKD was significantly associated with all-cause mortality, CHD, and CVA, whereas late VMS was associated with all-cause mortality. However, the presence of CKD did not modify the association of late VMS with mortality or CVD events.
The body of evidence characterizing menopausal symptoms in women with CKD is limited. Women receiving maintenance dialysis experience earlier onset of menopause (occurring between 46 and 48 y) 22 ,23 compared with the US median age of 51 years. 24 We found that women with primarily mild to moderate CKD also experienced, on average, earlier menopause. Lim et al 25 studied premenopausal women receiving dialysis and found hormone levels consistent with hypothalamic anovulation. They also noted a high prevalence of hyperprolactinemia, which may contribute to infertility by inhibiting gonadotropin secretion. 25 Although many women experience resumption of menses after renal transplantation, up to 31% of women with end-stage kidney disease experience no return of menses, and others who were menstruating before transplantation develop amenorrhea or abnormal menses after transplantation. 26, 27 Earlier menopause in women with CKD may also be attributable to the effect of CKD on the hypothalamic-pituitary axis, but this has not yet been studied in detail. CKD is characterized by accelerated aging, which is thought to be caused by uremic toxins, oxidative stress, and persistent inflammation. 28 We speculate that earlier menopause may represent a part of the accelerated aging phenotype of CKD through these pathways. Earlier menopause may have a variety of clinical implications, including potential adverse effects on bone health, cardiovascular risk, and sexual function, which may be affected by CKD via other pathways. 25 For instance, CKD is frequently associated with disturbances in bone and mineral metabolism, including demineralization attributable to secondary hyperparathyroidism. This could be exacerbated by early onset of menopause and further predispose women to fractures. Early onset of menopause may impair sexual function, which is also reported to be decreased in women with CKD. [29] [30] [31] Women with CKD experience premature CVD 32 ; given that VMS are associated with cardiovascular risk factors, we hypothesized that women with CKD would have a higher prevalence of VMS. To the contrary, we found that CKD was associated with a lower prevalence of VMS in this cohort. We speculate that preexisting vascular diseases among women with CKD, including vascular calcification, arterial stiffness, and impaired endothelial function, 33, 34 might interfere with the vasodilation required to expel heat in VMS. Alternatively, the lower prevalence of VMS among women with CKD may be related to lower body temperature 35, 36 in individuals with CKD or to alterations in the hypothalamic-pituitary axis. 37 Women with CKD may also be less inclined to report VMS because of competing symptoms or other health concerns.
Using data from the WHI, Szmuilowicz et al 8 showed that early VMS were associated with decreased risks of CVA, total CVD events, and all-cause mortality, whereas late VMS were associated with increased risks of CHD and all-cause mortality. In this subcohort of the WHI, we found that, after adjusting for CKD, late VMS remained a significant predictor of all-cause mortality, but there was no interaction between CKD and late VMS. In contrast to prior research, late VMS were not associated with CHD or CVA. This finding may be attributable to differences between the general WHI cohort and the biomarker cohort, which is smaller and more ethnically and racially diverse. We also had less power to demonstrate a modest association.
Our study has several limitations. VMS were ascertained by self-administered questionnaires, which may be subject to recall bias; for most participants in our study, menopause occurred several years before the measurement of kidney function. In the Study of Women's Health Across the Nation, the accuracy of VMS recall using a daily log of VMS was high (sensitivity, 78%-84%; specificity, 85%-89%). 38 Of note, the biomarker cohort is not a random sample of the WHI. Women in the biomarker cohort were older, more likely to be nonwhite, and less likely to have used HT ( Table 1 , Supplemental Digital Content 1, http://links.lww.com/MENO/A125); these differences may affect the association between CKD and VMS. Timing of menopause may not be accurate in women who have undergone a hysterectomy 39 ; however, the prevalence of hysterectomy was low in this cohort and was similar in women with CKD and women without CKD. We used a single measurement of serum creatinine as a marker of kidney function, and this may misclassify individuals with acute kidney disease rather than CKD. We also lacked urine albumin measurements, which would have improved our assessment of kidney disease and could have identified individuals with proteinuria but near-normal serum creatinine concentrations, many of whom have heightened cardiovascular risk.
CONCLUSIONS
In summary, women with predominantly mild CKD report earlier menopause, consistent with other body systems where diseases of aging appear earlier in the life course of CKD. Women with CKD also experience fewer VMS and less persistent VMS, suggesting that CKD may interfere with the pathogenesis of this condition. Further studies are needed to fully characterize how CKD influences other aspects of sex-specific health.
